The overall goal of the SECURED project is to scale up multiparty computation, data anonymization and synthetic data generation, by increasing efficiency and improving security, with a focus on private and unbiased artificial intelligence and data analytics, health-related data and data hubs, and cross-border cooperation. The project will address the limitations that are currently preventing the widespread use of secure multiparty computation and effective anonymization, namely: the limited practical capabilities of current cryptographic schemes for secure multi-party computation protocols, and their performance; the lack of well understood and standardized data anonymization methods for health data; the absence of dynamic and on demand services for generating synthetic data; the complex and ad-hoc nature of current federation protocols for machine learning and AI-based data analytics; the lack of support for health technology providers to implement privacy enhancing technologies, in particular SMEs. SECURED will tackle these challenges by focusing on scaling up privacy technologies via algorithmic improvements and implementation efficiency (HW and SW), as well as the generalization of primitives and definitions, with the aim of speeding up and facilitating privacy preserving data-driven tools and services for wellbeing, prevention, diagnosis, treatment and follow-up care. SECURED will also analyse the current ethical and legal challenges to data sharing, and is targeted at overcoming current limited adoption of advanced multi-party computation and data anonymization technologies by providing direct support to health technology SMEs through a funding call. To ensure relevance to real-world settings, SECURED will showcase the technologies developed in four health-related use cases provided by partner hospitals and health stakeholders, namely: real-time tumor classification; telemonitoring for children; synthetic data generation for education; access to genomic data.

Emergency Medical Services in Europe are characterised by a pluralistic landscape with diverse organisational setups, professional standards, coordination mechanisms and actors which result from different historical and institutional contexts in EU member states. However, diversity is united by the common aim, of providing timely care to victims of sudden and life-threatening injuries, emergencies or disasters within EU-member states (EUMS), in cross-border settings and international humanitarian missions. Fostering the response capacities and increasing the cooperation of the European Emergency Medical Services Systems (EMSS) is of decisive importance for strengthening the resilience of European societies in the light of multiple hazards: Climate change is increasing the frequency and severity of disasters, terrorism is becoming a very real scenario for mass causality events challenging both out-of-hospital as well as in-hospital emergency care, and health related hazards are calling for close cooperation of public safety and health authorities on an international level. Not only hazards but also the system’s diversity poses a challenge for preparedness planning and cooperation, which needs to involve the whole EMS system at regional and/or national level and integrate it into the whole health system and fully coordinate with the public safety system to be effective. The iProcureSecurity project seeks to identify the major challenges the system’s diversity poses to the ability to work together, stimulate R&I uptake with a view to increasing standardisation of operations across Europe, and deliver technical requirements for R&I activities to create a European system of Medical Emergency Teams that is more homogeneous and capable to work as singly unit. To achieve this aim, the project will engage in several exchange cycles with practitioners and other stakeholders in the innovation landscape as a preparation for major R&I activities as part of a PCP action.

Biomaterials in healthcare span almost all medical fields, ranging from recognised materials to high-innovative smart and multi-functional biomaterials. One of the main challenges is to provide accessible and well-structured data of biomaterials for all relevant practitioners and user groups. BIOMATDB aims to create an advanced database for biomaterials providing detailed information on its properties. Flexible data analysis and visualisation tools support the search and selection process based on analyses of the results of biological testing of biomaterials from the scientific literature to incorporate data on as many of the material properties as possible. BIOMATDB also provides a web-optimised information marketplace and digital advisors to support companies, especially SMEs, in offering their products and properly presenting themselves at global scale. Initiated by biomaterial use cases, the web application will match the suppliers and demanders through intelligent matching tools and step-by-step decision support. BIOMATDB focuses on the creation of a label of biocompatibility to define the suitability of a biomaterial for use in a medical device or advanced therapy and to assist companies, especially SMEs, in choosing and facilitating market access for their products providing them a better guidance. All created technical systems and data processing methods are tested within existing open innovation testbeds and validation groups. Intuitive training manuals and compact online video tutorials support the use of the database, marketplace and label. Appropriate business models are derived for securing the long-term sustainability of the created solutions. The project has a significant impact on the findability and searchability of existing biomaterials at the pan-European level. It is an enabler for better uptake of biomaterials in future health applications and medical therapies.

Accelerated digitalisation in health sector brings opportunities for cost-effective and efficient delivery of personalised care, through medical devices (including software) connected to IT networks and increasingly combined with novel technologies (AI, cloud computing, blockchain or 5G networks) and simultaneously Europe is witnessing an increase in the complexity and sophistication of attacks threatening such critical infrastructure. CYLCOMED addresses the overall ambitious goal of strengthening the cybersecurity of connected, in vitro diagnostic and software as medical devices (CMDs, IVDs, SaMD), maintaining their performance and safety for patients and preserving or enhancing the confidentiality, integrity and availability of private data they exchange or allow to be remotely accessed and focusing on humans operating the technology as the weakest link in the chain for security and privacy, with training and awareness measures tailored to healthcare staff needs. It does so by enabling adoption by all ecosystem stakeholders of technologically sovereign and trustworthy cybersecurity methodologies and toolboxes for connected medical devices and the environments in which they are managed and operate (platforms), complemented with fit-for-purpose guidance covering identifed risks and gaps. It will further deliver: (i) risk assessment framework with risk benefit analyses schemes and (ii) toolbox addressing cybersecurity risks and gaps in connected medical devices;(iii) assessment and extension of baseline standards, best practices and guidelines covering challenges for CMDs including SW, making them fit for purpose when used in conjunction with novel technologies; (iv) demonstrations and case studies in relevant on premise hospital scenarios (COVID-19 patients monitoring) and remote telemonitoring scenarios improving the life of paediatric patients. CYLCOMED has 9 partners from 7 EU Member States and 1 associate partner from Switzerland and a duration of 36 months.